Business
Clearmind Medicine Announces Share-Based Payment for the Company's Consultants
Tel Aviv, Israel / Vancouver, Canada, July 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the
About this update from Clearmind Medicine Inc.
[{"type":"text","content":"Tel Aviv, Israel / Vancouver, Canada, July 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the \"company\"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has issued 17,899 common shares in the capital of the Company (\"Shares\") in lieu of the final payment of $10,000, starting May 1st 2022, to consultants of the Company. In addition, the Company has issued restricted stock units (\"RSUS\") for additional consultant in lieu of payment of $5,000. All Shares will only be subjected to those restrictions designated in applicable securities laws. About Clearmind Medicine Inc. Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company’s intellectual portfolio currently consists of fourteen patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed on Nasdaq and the Canadian Securities Exchange under the symbol \"CMND\" and the Frankfurt Stock Exchange under the symbol “CWY.” For further information visit: www.clearmindmedicine.com or contact: Investor [email protected]: (604) 260-1566US: [email protected] General [email protected] FORWARD-LOOKING STATEMENTS: This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its clinical trial collaborations, and the potential therapeutic benefit of its product candidate...